Moderate

Leprosy (Hansen disease)

Leprosy · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Leprosy is chronic infection by Mycobacterium leprae/lepromatosis affecting skin and peripheral nerves, classified across a spectrum from paucibacillary to multibacillary. Multidrug therapy cures infection; immune reactions can cause acute nerve damage.

Red flags

  • Acute nerve pain/tenderness or new weakness (reaction - emergency for nerves)
  • Loss of sensation threatening hands/feet/eyes
  • Severe erythema nodosum leprosum with systemic illness
  • Eye involvement risking blindness
  • Rapidly progressive neuritis

Assessment

Differential diagnosis

  • Other causes of peripheral neuropathy
  • Fungal/other granulomatous skin disease
  • Cutaneous leishmaniasis
  • Sarcoidosis
  • Vitiligo / other hypopigmented dermatoses

Investigations

  • Slit-skin smears for acid-fast bacilli (bacillary index)
  • Skin and/or nerve biopsy with histology
  • Assessment of peripheral nerve thickening and sensory/motor function
  • Classification (number of lesions, smear positivity)
  • Baseline G6PD before dapsone
  • Monitoring of nerve function over time

Management

  • Diagnose via characteristic anaesthetic skin lesions and/or thickened nerves with AFB
  • Classify as paucibacillary or multibacillary (lesion count and smears)
  • Check G6PD status before dapsone
  • Start WHO multidrug therapy appropriate to classification
  • Educate on long treatment, adherence and the need to report reactions
  • Assess and protect anaesthetic hands/feet/eyes (disability prevention)
  • Recognise and treat leprosy reactions (type 1 reversal, type 2 ENL) urgently to save nerves
  • Use corticosteroids for neuritis/reactions; thalidomide for severe ENL where available
  • Provide physiotherapy and footwear/eye care to prevent deformity
  • Screen household contacts and consider single-dose rifampicin prophylaxis
  • Monitor for drug toxicity and clinical response
  • Arrange long-term rehabilitation and follow-up

Drugs & doses

Multibacillary: rifampicin 600 mg monthly + dapsone 100 mg daily + clofazimine 300 mg monthly/50 mg daily for 12 months
Paucibacillary: rifampicin 600 mg monthly + dapsone 100 mg daily (+ clofazimine) for 6 months
Prednisolone 40-60 mg PO daily tapering for type 1 reactions/neuritis
Thalidomide 100-300 mg PO daily for severe type 2 (ENL) reactions (not in pregnancy)
Single-dose rifampicin 600 mg for eligible contacts (post-exposure prophylaxis)

Disposition

Outpatient leprosy/dermatology service; admit for severe reactions; long-term rehabilitation.

Complications & pitfalls

  • Permanent nerve damage and deformity
  • Trophic ulcers and secondary infection
  • Blindness
  • Leprosy reactions (type 1 and type 2/ENL)
  • Dapsone haemolysis/hypersensitivity

Exam pearls

  • Reactions are the main cause of nerve damage - treat promptly with corticosteroids
  • WHO multidrug therapy renders patients non-infectious quickly
  • Check G6PD before dapsone to avoid severe haemolysis
  • Disability prevention (self-care of anaesthetic limbs) is as important as antibiotics
  • Single-dose rifampicin reduces leprosy risk in contacts

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.